ArticleInternational journal of bipolar disorders2026
Methodological concerns limiting the detection of treatment effects in the OSAN trial of blue-blocking glasses for mania.
Article in International journal of bipolar disorders, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThis correspondence is a commentary to the recently published report from the OSAN trial by Fiedorowicz et al. but with applicability to the broader research involving blue-blocking glasses and patients in a manic episode.
methodClinical studies on dark therapy are still rare, and we read with great interest the report from the OSAN trial published in Journal of Affective Disorders the 1st of April 2026.
resultsThe sample was significantly higher in manic symptoms, more medicated and less adherent to the intervention than in preceding studies on effects of dark therapy for mania. Efforts to comply with the gold standard of blinding of raters may have come with the cost of underestimating the symptom level. Extended intervention period (2 weeks) may have caused the extensive loss to follow up (35/42 (83%) at 2 weeks). Several issues with the statistical methods and data reporting make the results difficult to interpret.
conclusionsThe statistical power of the OSAN trial may have been substantially reduced by attrition and multiple sources of variance to the data. The results from the trial should be interpreted with caution.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.